Saltar al contenido
Merck

H0393

Sigma-Aldrich

Hirudin

recombinant, expressed in unspecified host, ≥7,000 ATU/mg protein, powder

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Número de CAS:
EC Number:
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.77

product name

Hirudin, recombinant, expressed in unspecified host, ≥7,000 ATU/mg protein (ATU = antithrombin units)

recombinant

expressed in unspecified host

Quality Level

form

powder

specific activity

≥7,000 ATU/mg protein (ATU = antithrombin units)

mol wt

~7 kDa

solubility

pyridine: soluble
water: soluble

shipped in

dry ice

storage temp.

−20°C

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Antithrombotic efficacy by parenteral route is substantially prolonged by incorporation into cationic liposomes, which act as a sort of sustained-release device.

Physical properties

The anticoagulant hirudin is a ~7 kDa acidic protein containing 65 amino acid residues. It occurs naturally in leeches (Hirudo medicinalis). It is the most potent natural inhibitor of both soluble and clot-bound thrombin. Hirudin binds thrombin with high affinity and covers more than 20% of the surface area of thrombin, occluding both the active site and exosite I (fibrinogen and PAR recognition site). This coverage blocks thrombus growth and platelet activation. Hirudin is not metabolized in the bloodstream of humans and is eliminated unchanged via kidney filtration. Native hirudin contains a sulfated tyrosyl residue (Tyr63), three disulfide bridges, and a high proportion of dicarboxylic acids. Hirudin is not glycosylated, and lacks tryptophan, arginine, and methionine residues. At least 20 isoforms have been identified and sequenced.
This recombinant hirudin product corresponds to the HV-1 variant sequence, with the exception that the Tyr63 residue is not sulfated.

Unit Definition

One antithrombin unit (ATU) will neutralize one NIH unit of thrombin at 37 °C, based on direct comparison to an NIH thrombin reference standard.

Reconstitution

Hirudin is soluble in water. The literature cites the use of "Dilution Fluid II" (35.7 mM acetic acid, 35.7 mM sodium diethyl barbiturate, 0.85% NaCl, 1% bovine serum albumin, and 0.5% PEG, pH 7.4) to dissolve hirudin (500 ATU/mL) and thrombin. Hirudin is reported to be soluble in pyridine, but practically insoluble in alcohol, ether, acetone, or benzene.

Analysis Note

Protein determined by Lowry.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

R Bischoff et al.
Biochemistry, 32(2), 725-734 (1993-01-19)
Natural hirudin variant 2 with a lysine residue in position 47 (rHV2-Lys47) was produced in a genetically engineered strain of Saccharomyces cerevisiae as a secreted protein of 65 amino acids and purified to greater than 99% homogeneity. Only reversed-phase high-performance
The complete amino acid sequence of hirudin, a thrombin specific inhibitor: Application of colour carboxymethylation.
Dodt, J., et al.
Febs Letters, 165, 180-184 (1984)
A Kudo et al.
Cerebrovascular diseases (Basel, Switzerland), 10(6), 424-430 (2000-11-09)
The role of thrombin as a spasmogen after subarachnoid hemorrhage was evaluated using the intrathecally administered thrombin inhibitor hirudin, released from a drug delivery system (DDS) based on collagen in a canine vasospasm model. The DDS was implanted into the
Serdar Duzgun et al.
Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India, 47(1), 102-108 (2014-07-06)
The effect of recombinant hirudin, which is the most powerful antithrombotic agent, on flaps with venous insufficiency was investigated. Oedema and congestion are frequent on flaps, causing necrosis unpredictably. Venous insufficiency and thrombosis are experimentally and clinically more frequent than
Hirudin and hirudin-based peptides.
S R Stone et al.
Methods in enzymology, 223, 312-336 (1993-01-01)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico